| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 05/11/2022 | 3. Issuer Name and Ticker or Trading Symbol Moderna, Inc. [ MRNA ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 2,583 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | 03/01/2023(1) | 03/01/2032 | Common Stock | 26,020 | 149.52 | D | |
| Restricted Stock Units | (2) | (2) | Common Stock | 6,415 | 0 | D | |
| Restricted Stock Units | (3) | (3) | Common Stock | 3,830 | 0 | D | |
| Stock Option (Right to Buy) | 02/09/2022(4) | 02/09/2031 | Common Stock | 25,618 | 179.52 | D | |
| Stock Option (Right to Buy) | 07/06/2021(5) | 07/06/2030 | Common Stock | 271,303 | 59.15 | D | |
| Explanation of Responses: |
| 1. 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| 2. 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| 3. 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| 4. 25% of this option vested and became exercisable on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| 5. 25% of this option vested and became exercisable on July 6, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| Remarks: |
| The Reporting Person retired as Chief Financial Officer of the Issuer on May 9, 2022 but was reappointed as Chief Financial Officer of the Issuer on May 11, 2022 as reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 11, 2022. |
| /s/ Brian Sandstrom, as Attorney-in-Fact | 05/12/2022 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
